[{"abstract": "If you pay rent to a property management company with the aim of eventually owning the place, are you a renter or a homeowner? Some companies are blurring that line.", "web_url": "https://www.nytimes.com/2016/08/22/business/dealbook/landlords-tenants-pfizer-medivation-private-equity-pace.html", "snippet": "If you pay rent to a property management company with the aim of eventually owning the place, are you a renter or a homeowner? Some companies are blurring that line.", "lead_paragraph": "If you pay rent to a property management company with the aim of eventually owning the place, are you a renter or a homeowner? Some companies are blurring that line.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Morning Agenda: Tenants Struggle in Win-Win Contracts for Landlords", "kicker": null, "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Renting and Leasing (Real Estate)", "rank": 1, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 2, "major": "N"}, {"name": "organizations", "value": "Medivation Inc", "rank": 3, "major": "N"}, {"name": "subject", "value": "Elder Care", "rank": 4, "major": "N"}, {"name": "subject", "value": "Medicare", "rank": 5, "major": "N"}, {"name": "subject", "value": "Private Equity", "rank": 6, "major": "N"}], "pub_date": "2016-08-22T09:58:53+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By Amie Tsang", "person": [{"firstname": "Amie", "middlename": null, "lastname": "Tsang", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/03ba9b4b-0d9e-5ae7-9b33-6bc98aaa1d1f", "word_count": 569, "uri": "nyt://article/03ba9b4b-0d9e-5ae7-9b33-6bc98aaa1d1f"}, {"abstract": "The frenzy over Medivation, which makes treatments for prostate and breast cancers, shows what pharmaceutical companies are willing to pay for oncology deals.", "web_url": "https://www.nytimes.com/2016/08/23/business/dealbook/medivation-pfizer-14-billion-deal.html", "snippet": "The frenzy over Medivation, which makes treatments for prostate and breast cancers, shows what pharmaceutical companies are willing to pay for oncology deals.", "lead_paragraph": "Medivation, which makes the big-selling drug Xtandi to treat prostate cancer, has finally found its buyer in a fellow American drug maker, Pfizer.", "print_section": "B", "print_page": "1", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2016/08/23/business/23DB-MEDIVATION2/23DB-MEDIVATION-1471896501249-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2016/08/23/business/23DB-MEDIVATION2/23DB-MEDIVATION-1471896501249-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2016/08/23/business/23DB-MEDIVATION2/23DB-MEDIVATION-1471896501249-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}, {"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2016/08/23/business/23DB-MEDIVATION2/23DB-MEDIVATION-1471896501249-articleLarge.jpg", "height": 366, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2016/08/23/business/23DB-MEDIVATION2/23DB-MEDIVATION-1471896501249-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 366}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2016/08/23/business/23DB-MEDIVATION2/23DB-MEDIVATION-1471896501249-jumbo.jpg", "height": 625, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2016/08/23/business/23DB-MEDIVATION2/23DB-MEDIVATION-1471896501249-superJumbo.jpg", "height": 1251, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}], "headline": {"main": "Pfizer to Buy Cancer Drug Maker in $14 Billion Deal", "kicker": null, "content_kicker": null, "print_headline": "Pfizer Pays $14 Billion to Expand in Oncology", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "Medivation Inc", "rank": 1, "major": "N"}, {"name": "persons", "value": "Picker, Leslie", "rank": 2, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 3, "major": "N"}, {"name": "persons", "value": "Pollack, Andrew", "rank": 4, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 5, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 6, "major": "N"}], "pub_date": "2016-08-22T12:03:13+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By Andrew Pollack and Leslie Picker", "person": [{"firstname": "Andrew", "middlename": null, "lastname": "Pollack", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}, {"firstname": "Leslie", "middlename": null, "lastname": "Picker", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 2}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/dcd0f2b8-e2ac-5b6b-9b61-410ffd022292", "word_count": 1244, "uri": "nyt://article/dcd0f2b8-e2ac-5b6b-9b61-410ffd022292"}, {"abstract": "A heated auction and back-of-the-envelope math hint that the buyer is overpaying.", "web_url": "https://www.nytimes.com/2016/08/23/business/dealbook/the-flaws-in-pfizers-plan-to-acquire-medivation.html", "snippet": "A heated auction and back-of-the-envelope math hint that the buyer is overpaying.", "lead_paragraph": "Pfizer seems to know something others do not about the biotech company Medivation.", "source": "The New York Times", "multimedia": [], "headline": {"main": "The Flaws in Pfizer\u2019s Plan to Acquire Medivation", "kicker": "Breakingviews", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 1, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 2, "major": "N"}, {"name": "organizations", "value": "Medivation Inc", "rank": 3, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Astellas Pharma", "rank": 5, "major": "N"}], "pub_date": "2016-08-22T20:05:15+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By Robert Cyran", "person": [{"firstname": "Robert", "middlename": null, "lastname": "Cyran", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/dcca7dbf-9072-50c6-a62d-162fd6851b1b", "word_count": 376, "uri": "nyt://article/dcca7dbf-9072-50c6-a62d-162fd6851b1b"}]